# Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure

> **NCT00521820** · PHASE3 · TERMINATED · sponsor: **Takeda** · enrollment: 518 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Pioglitazone
- **DRUG:** Glyburide

## Key facts

- **NCT ID:** NCT00521820
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-06
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** 518 (ACTUAL)
- **Why stopped:** Higher incidence of hospitalization for congestive heart failure in pioglitazone-treated subjects compared to glyburide treated subjects.
- **Last updated:** 2012-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00521820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00521820, "Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00521820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*